Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Oligodendroglioma 1Glioma 1Glioblastoma 1Astrocytoma 1

Interventions

Magnetic Resonance Spectroscopy 287Specimen Handling 285pembrolizumab 258Cyclophosphamide 237Radiotherapy 233Nivolumab 187Cisplatin 174Biopsy 170Carboplatin 155Radiosurgery 142fludarabine 131Blood Specimen Collection 130Surveys and Questionnaires 120Gemcitabine 120Paclitaxel 115venetoclax 114Standard of Care 112Dexamethasone 105Bevacizumab 98Radiation 97Rituximab 92Oxaliplatin 89Cytarabine 88Capecitabine 88Drug Therapy 86Ipilimumab 85Doxorubicin 83durvalumab 81atezolizumab 76fludarabine phosphate 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × vocimagene amiretrorepvec × 90 days × Clear all
NCT04105374 2026-05-07

Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma

NRG Oncology

Phase 2/3 Withdrawn
CNS

Astrocytoma, Glioblastoma, Oligodendroglioma

NCT06504381 2026-03-11

DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma

University of California, San Francisco

Phase 1/2 Recruiting
70 enrolled
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡